Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers

In Phase III KEYNOTE-407 of squamous NSCLC, Keytruda/chemo combo shows overall survival benefit, which was reassuring news for doctors – and investors – ahead of ASCO.

Merck & Co. Inc.'s announcement that its PD-1 inhibitor Keytruda combined with chemotherapy demonstrated overall survival and progression-free survival benefits in the KEYNOTE-407 study in first-line squamous non-small lung cancer (NSCLC) support the drug's role in this indication and dominance in the tumor type generally.

Merck announced May 23 that the combination of Keytruda (pembrolizumab) and chemo demonstrated benefits for the co-primary endpoints of progression-free...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip